Results 61 to 70 of about 4,565 (213)

Nieuwe antibiotica werkzaam tegen multiresistente gramnegatieve bacteriën [PDF]

, 2021
Infecties door gramnegatieve bacteriën zijn lastig te behandelen wanneer deze bacteriën resistent zijn voor β-lactamantibiotica. De afgelopen 5 jaar zijn door het Europees Geneesmiddelenbureau en het Amerikaanse Food and Drug Administration nieuwe ...
Bax, Hannelore, Dix, Laura, van Westreenen, Mireille, Verkaik, Nelianne, Yusuf, Erlangga   +4 more
core  

Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae [PDF]

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
Vaborbactam (VAB; formerly RPX7009) is a novel beta‐lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against Ambler class A and C beta‐lactamases. It has been co‐formulated with meropenem to restore its activity against Klebsiella pneumoniae carbapenemases (KPC).
Sarah Christina Jane Jorgensen, Michael Joseph Rybak   +1 more
openaire   +2 more sources

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

International Journal of Infectious Diseases, 2021
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI).
Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes   +3 more
doaj   +1 more source

Antimicrobial treatment challenges in the era of carbapenem resistance [PDF]

, 2019
Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a new era in which antibiotic resistance in Gram-negative bacilli is being dealt
Doi, Yohei, Harris, Patrick N.A., Paterson, David L., Peri, Anna Maria, Potoski, Brian A., Righi, Elda   +5 more
core   +1 more source

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying blaKPC Collected Worldwide [PDF]

Open Forum Infectious Diseases, 2017
Abstract Background Meropenem-vaborbactam (MER-VAB) is a carbapenem-β-lactamase inhibitor combination with enhanced activity against KPC-producing Enterobacteriaceae recently evaluated in a phase 3 clinical trials for cUTIs and infections due to CRE.
Castanheira, Mariana, Mendes, Rodrigo E, Duncan, Leonard R, Woosley, Leah N, Flamm, Robert K   +4 more
openaire   +1 more source

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li, Fei Zeng, Jie Zhang, Yuangong Zhang, Wenjuan Yin   +4 more
wiley   +1 more source

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

Infection and Drug Resistance, 2018
Lindsay A Petty,1 Oryan Henig,1 Twisha S Patel,2 Jason M Pogue,3 Keith S Kaye1 1Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Pharmacy Services, University of ...
Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS   +4 more
doaj  

Carbapenemase-producing organisms: a global scourge [PDF]

, 2018
The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern.
Bonomo, Robert A, Burd, Eileen M, Conly, John, Limbago, Brandi M, Poirel, Laurent, Segre, Julie A, Westblade, Lars F   +6 more
core  

Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem‐Resistant Klebsiella pneumoniae (CRKP) Infections

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Carbapenem‐resistant Klebsiella pneumoniae (CRKP) has become a global public health threat, with significantly increased morbidity and mortality among high‐risk inpatients. High‐risk genotypes of CRKP, primarily including K. pneumoniae carbapenemase (KPC), oxacillinase‐48–like (OXA‐48–like), New Delhi metallo‐β‐lactamase (NDM), imipenemase ...
Qiongfang Zhang, Ze Fang, Bo Fang, Hailing Zeng, Jiaojiao Xu, Muhammad Abu Bakr Shabbir   +5 more
wiley   +1 more source